Find out more about San Diego life science companies as we explore the latest technologies, drug discoveries, financing, IP updates and more.

  • How safe is the safe harbor?

    A safe harbor is a provision of a statute or a regulation that reduces or eliminates a party's liability under the law, on the condition that the party performed its actions in good faith. A recent decision by the Federal Circuit court has interpreted the scope of a safe harbor from patent infringement for companies pursuing U.S. Food and Drug Administration (FDA) product approval, including pharmaceutical drugs, protein drugs, many medical devices and food additives.

  • San Diego institutions recipients of more than $120 million in CIRM funds

    On the surface, fruit flies don't appear to have a lot to do with stem cell research. But Dr. Leanne Jones of the Salk Institute for Biological Studies thought she could learn a lot about the complex human system by studying the more basic structures of the tiny winged insects.

  • Biotech trends: Global partnering, mergers, acquisitions

    Stakeholders across the biotech industry have varied viewpoints about funding and industry trends, but all agree on two aspects -- the economic crisis will only have a marginal impact on the industry, and change is imminent across the board, from the approach to funding to strategic partnerships.

  • Nexus Science Center in UTC ready for tenant improvements

    Building One of the Nexus University City Science Center, currently under construction at the northwest corner of La Jolla Village Drive and Interstate-805, is ready for tenant improvement work. Nexus University City Science Center is a two-building biotech/R&D development, totaling approximately 161,871 square feet, located in the heart of the UTC life science cluster. Building One totals 58,924 square feet.

  • Rudolph and Sletten: Building biotech facilities in San Diego for two decades

    The quality of scientific research within the field of biotechnology often depends on the caliber and capability of the industry's labs and research facilities. Quality science and quality construction converge at Rudolph and Sletten, one of the state's leading builders of biotechnology facilities.

  • Reno Contracting and San Diego lead biotech industry's growth

    With more than 700 manufacturing, diagnostic and traditional biotech firms in San Diego County, this region has become one of the leading centers for the biotechnology industry. An integral part of that growth is San Diego's Reno Contracting, founded in 1993 by CEO Matt Reno. The general contractor has been a major contributor in San Diego's biotech, commercial and retail building growth. Walt Fegley, president of Reno Contracting, noted that his company has been at the forefront in biotech because "we have the preconstruction, technical and building experience to deliver complex projects on time and on budget."

  • Fish & Richardson: Protecting biotechs

    As the old saying goes, there is safety in numbers. When a biotechnology or pharmaceutical company hires Fish & Richardson, it is hiring a 130-year old law firm with almost 500 attorneys, including 80 who have Ph.D.s, 12 offices worldwide, the experience of a firm that files 5,400 patent applications annually and handles more patent litigation than any other law firm in the world, and the expertise that will keep a company's inventions and business interests safe and secure.

  • Lung cancer vaccine trial launched at Moores UCSD Cancer Center

    Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off advanced lung cancer by treating patients with a novel kind of cancer vaccine. While many vaccines attempt to pump up the immune system to fight off a cancer, the new vaccine, Lucanix, is genetically engineered to also trick the cancer into turning off its immune system-suppressing activities.

  • Patent prosecution highway program: European expansion

    As the volume of global patent filings rises, patent offices around the world continue to face increasing patent administration demands. Currently, applicants for U.S. biotechnology and organic chemistry patents can expect an average of close to two years before a first action by the U.S. Patent and Trademark Office (USPTO), and a total average patent application pendency of close to three years. As part of an effort to address the challenges presented by such backlog, on Sept. 22, the USPTO announced the establishment of a one-year Patent Prosecution Highway (PPH) pilot program between the USPTO and the European Patent Office (EPO), effective Sept. 29.

  • Prevost Construction brings experience, commitment to local biotech industry

    For nearly 20 years, Prevost Construction has played a key role in the biotech industry by offering a highly specialized approach to the construction process, by combining its deep understanding of these complex facilities with its ability to perform cost-effective tenant improvements in the remodeling of existing facilities.

  • Life science market bright spot in local economy

    At a time when many commercial real estate sectors are slowing, the San Diego County life sciences market continues to grow with biotechnology and market research ranking among the region's top performing industry sectors.

  • CIRM funding: Worth the cost?

    In 2004, the voters of California approved Proposition 71, which provided $3 billion dollars over 10 years to support stem cell research not funded by the federal government. Since then, the California Institute for Regenerative Medicine (CIRM) has made two moves affecting businesses: finalizing rules regulating the intellectual property (IP) rights of for-profit grantees of CIRM funds ("rules") in December 2007, and approving an outline of a plan to set aside $500 million in loan funds for companies on Sept. 25. Now that IP rights are clearer and funds are becoming available, how do San Diego stem cell-focused companies make the decision as to whether or not to apply for CIRM funds?

  • Contract research organization Synteract works hand in hand with clients

    Carlsbad-based Synteract was founded in 1995 by Ellen Morgan, the president and CEO of the company, who won the Athena Pinnacle award for the services industry this year and by Russ Holmes, the executive vice president.

  • Home-based diagnostic test kits at forefront of growing trend

    San Diego-based Confirm BioSciences manufactures and distributes the kind of products that bring either peace of mind or confirmation of a suspicion for many parents of teenagers across the country -- diagnostics test kits such as HairConfirm that discreetly test for drugs using a hair follicle, thereby eliminating the need for arguments and trips to a laboratory.

  • Invitrogen files patent lawsuit

    Carlsbad-based Invitrogen Corp. (Nasdaq: IVGN) has filed a patent lawsuit against Oxford Biomedical Research Inc. and Vanderbilt University in the U.S. District Court in western Wisconsin.

  • UCSD Professor Tsien receives Nobel Prize

    While a room full of scientists and academics gathered this morning to recognize University of California San Diego Professor Roger Tsien for winning a Nobel Prize, he recognized jellyfish.

  • IP officials debate patent changes

    Recent judicial action along with some changes in the patent office have begun to weaken the U.S. patent system, according to a panel of intellectual property experts hosted by Knobbe Martens Olson & Bear last week.

  • Cardinal Health to headquarter spin-off in San Diego

    Global healthcare company Cardinal Health announced plans Monday to spin-off its clinical and medical products businesses as a separate public company to be based in San Diego.

  • Qualcomm sees future in wireless, life science convergence

    An awards luncheon Tuesday by Qualcomm Inc. highlighted the company’s growing interest in combining its wireless technology with the medical and life science fields.

  • Eli Lilly to locate West Coast operations in San Diego

    Leading pharmaceutical company Eli Lilly and Co. (NYSE: LLY) has reportedly leased property in University Towne Center for its West Coast biotech center.

  • Tech Coast Angels closes series A financing for Amplyx Pharmaceuticals

    San Diego Tech Coast Angels, a member of the largest angel network in the United States, announced that Tech Coast Angels and Life Science Angels have partnered to close a Series A financing for Amplyx Pharmaceuticals Inc., a Menlo Park-based drug development company focused on creating best-in-class small molecule drugs.

Inside Biotech

Roundtables

  • Patent laws to have far-reaching effects on business, economy

    According to Alan Hammond, chief intellectual property counsel for San Diego biotech company Invitrogen (Nasdaq: IVGN), in the mid-1970s, roughly 20 percent of all market value was in intangible property, including assets like intellectual property. Today, that number is roughly 80 percent.

Profiles

Archived Reports

Inside Biotech - 2014

Learn about innovations and trends in San Diego’s thriving biotech and life science industries.

Inside Biotech - 2011

Take an in-depth look at San Diego's vibrant life sciences sector with our annual publication, Inside Biotech.

Inside Biotech - 2009

Explore the latest technologies, newest medical and drug discoveries, financing, IP issues and more.

Inside Biotech - 2007

The Daily Transcript takes an in-depth look at the biotech sector, including financing, educational needs and the latest research coming out of local companies.

Inside Biotech - 2006

This special report takes an in-depth look at the biotech sector of our local economy. We'll discuss what's going on in the biotech arena from many angles and explore the latest technologies used in drug discovery. We'll also review the latest intellectual property news.

Inside Biotech - 2005

The Women's Business Center of California Business to Business Expo is all about women-owned businesses showcasing their products and services to other women and the business community at large. The event will be held Thursday, Oct. 20, from 9:30 a.m. to 1 p.m. at National University, 9388 Lightwave Ave.